Cargando…
The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial
PURPOSE: Concomitant vitamin D deficiency (VDD) is speculated to aggravate diabetic macular edema (DME). We aimed to determine the effect of hypovitaminosis D correction on the outcome of treatment with intravitreal bevacizumab (IVB) in DME eyes. METHODS: In this randomized clinical trial, 83 eyes o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093557/ https://www.ncbi.nlm.nih.gov/pubmed/35543853 http://dx.doi.org/10.1007/s10792-022-02333-2 |
_version_ | 1784705358542929920 |
---|---|
author | Fekri, Sahba Soheilian, Masoud Roozdar, Sepehr Abtahi, Seyed-Hossein Nouri, Hosein |
author_facet | Fekri, Sahba Soheilian, Masoud Roozdar, Sepehr Abtahi, Seyed-Hossein Nouri, Hosein |
author_sort | Fekri, Sahba |
collection | PubMed |
description | PURPOSE: Concomitant vitamin D deficiency (VDD) is speculated to aggravate diabetic macular edema (DME). We aimed to determine the effect of hypovitaminosis D correction on the outcome of treatment with intravitreal bevacizumab (IVB) in DME eyes. METHODS: In this randomized clinical trial, 83 eyes of 83 patients with DME were recruited and divided into three groups: normal vitamin D levels + IVB administration (Group 1), vitamin D insufficient/deficient + IVB administration (Group 2), and vitamin D insufficient/deficient + IVB administration + oral vitamin D supplementation (Group 3). Participants were followed for 6 months after the intervention. Visual (corrected distance visual acuity, CDVA) and anatomical (central macular thickness, CMT) outcomes of intervention were evaluated 1, 3, and 6 months after three monthly loading doses of IVB were given. Serum vitamin D levels were measured 1 and 6 months after the third IVB administration. RESULTS: A total of 29, 26, and 28 eyes were enrolled in groups 1, 2, and 3, respectively. In months 1, 3, and 6, after the three basic loading doses of IVB, visual acuity and CMT improved in all three groups, but improvements (both functional and anatomical) in groups 1 and 3 in month 6 were more significant than in group 2 (mean CDVA LogMAR changes: − 0.18 ± 0.03, − 0.14 ± 0.05, and − 0.2 ± 0.06; mean CMT reductions: − 82.24 ± 11.43, − 66.62 ± 14.34, and − 86.14 ± 18.36, in groups 1, 2, and 3, respectively; p < 0.001). The mean number of IVB injections during follow-up was 5.33 (range 4–7), which did not differ between the groups. CONCLUSION: Correction of vitamin D deficiency in DME patients with type 2 diabetes and vitamin D deficiency, in addition to IVB injections, may play a role in improving CDVA and CMT. However, this beneficial effect seems to be delayed by several months. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20200407046978N1, registered on April 11, 2020, retrospectively registered (https://en.irct.ir/trial/46999). |
format | Online Article Text |
id | pubmed-9093557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-90935572022-05-12 The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial Fekri, Sahba Soheilian, Masoud Roozdar, Sepehr Abtahi, Seyed-Hossein Nouri, Hosein Int Ophthalmol Original Paper PURPOSE: Concomitant vitamin D deficiency (VDD) is speculated to aggravate diabetic macular edema (DME). We aimed to determine the effect of hypovitaminosis D correction on the outcome of treatment with intravitreal bevacizumab (IVB) in DME eyes. METHODS: In this randomized clinical trial, 83 eyes of 83 patients with DME were recruited and divided into three groups: normal vitamin D levels + IVB administration (Group 1), vitamin D insufficient/deficient + IVB administration (Group 2), and vitamin D insufficient/deficient + IVB administration + oral vitamin D supplementation (Group 3). Participants were followed for 6 months after the intervention. Visual (corrected distance visual acuity, CDVA) and anatomical (central macular thickness, CMT) outcomes of intervention were evaluated 1, 3, and 6 months after three monthly loading doses of IVB were given. Serum vitamin D levels were measured 1 and 6 months after the third IVB administration. RESULTS: A total of 29, 26, and 28 eyes were enrolled in groups 1, 2, and 3, respectively. In months 1, 3, and 6, after the three basic loading doses of IVB, visual acuity and CMT improved in all three groups, but improvements (both functional and anatomical) in groups 1 and 3 in month 6 were more significant than in group 2 (mean CDVA LogMAR changes: − 0.18 ± 0.03, − 0.14 ± 0.05, and − 0.2 ± 0.06; mean CMT reductions: − 82.24 ± 11.43, − 66.62 ± 14.34, and − 86.14 ± 18.36, in groups 1, 2, and 3, respectively; p < 0.001). The mean number of IVB injections during follow-up was 5.33 (range 4–7), which did not differ between the groups. CONCLUSION: Correction of vitamin D deficiency in DME patients with type 2 diabetes and vitamin D deficiency, in addition to IVB injections, may play a role in improving CDVA and CMT. However, this beneficial effect seems to be delayed by several months. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20200407046978N1, registered on April 11, 2020, retrospectively registered (https://en.irct.ir/trial/46999). Springer Netherlands 2022-05-11 2022 /pmc/articles/PMC9093557/ /pubmed/35543853 http://dx.doi.org/10.1007/s10792-022-02333-2 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Fekri, Sahba Soheilian, Masoud Roozdar, Sepehr Abtahi, Seyed-Hossein Nouri, Hosein The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title | The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title_full | The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title_fullStr | The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title_full_unstemmed | The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title_short | The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
title_sort | effect of vitamin d supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093557/ https://www.ncbi.nlm.nih.gov/pubmed/35543853 http://dx.doi.org/10.1007/s10792-022-02333-2 |
work_keys_str_mv | AT fekrisahba theeffectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT soheilianmasoud theeffectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT roozdarsepehr theeffectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT abtahiseyedhossein theeffectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT nourihosein theeffectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT fekrisahba effectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT soheilianmasoud effectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT roozdarsepehr effectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT abtahiseyedhossein effectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial AT nourihosein effectofvitamindsupplementationontheoutcomeoftreatmentwithbevacizumabindiabeticmacularedemaarandomizedclinicaltrial |